<DOC>
	<DOC>NCT02429102</DOC>
	<brief_summary>The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of MT-8554 in healthy Caucasian subjects.</brief_summary>
	<brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy and free from clinically significant illness or disease Male or female subjects aged 18 to 55 years or elderly male subjects aged ≥65 A body weight of ≥60 kg male and ≥50 kg female Participation in more than three clinical studies involving administration of an Investigational Medicinal Product (IMP) in the previous year, or any study within 12 weeks. Clinically significant endocrine, thyroid, hepatic, respiratory, gastrointestinal, renal, cardiovascular disease, or history of any significant psychiatric/psychotic illness disorder. Clinically relevant abnormal medical history, physical findings or laboratory values</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy subjects</keyword>
	<keyword>Pharmacokinetics of MT-8554</keyword>
</DOC>